Market Overview

RBC Says New Dosing for Allergan's DARPin Could Be Positive for Regeneron's Eylea

Share:
Related REGN
The 5 Biggest Biotech Stocks
Notes From The Street: 'FLASHBACK....Oil Going To $200/Barrel'
Making Money With Charles Payne: 12/22/14 (Fox Business)
Related AGN
Valeant CEO On Allegations Against The Company And Future M&A Deals
What Investors Are Expecting Ahead Of Multiple Nektar Therapeutics Catalysts
Energy Sector Seen as Biggest Risk to Deal Flow in 2015 (Fox Business)

RBC's Adnan Butt issued a note Wednesday morning suggesting the every-other-month dosing of Allergen's (NYSE: AGN) DARPin may solidify the longer-term market position for Regeneron's (NASDAQ: REGN) Eylea.

The analyst pointed out Allergan's Phase 2 study evaluating this same method "in a schedule almost identical to Eylea's."

RBC sees the study completed later this year, with the Phase 3 trial slated for completion by yearend 2014 or early 2105. This schedule of studies could indicate DARPin sales starting as soon as 2019.

RBC maintains an Outperform rating and $286 price target on shares of Regeneron Pharma.

Latest Ratings for REGN

DateFirmActionFromTo
Jan 2015CitigroupMaintainsBuy
Jan 2015BarclaysInitiates Coverage onEqual-weight
Jan 2015Morgan StanleyUpgradesEqualweightOverweight

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings

 

Related Articles (REGN + AGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional